Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00629447 · ClinicalTrials.gov registry record · NA
Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT00629447 is a NA study that has completed, run by Duke University. The registered enrollment target is 40 participants.
The verdict
NCT00629447, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
To determine the safety of prophylaxis with Tinzaparin low molecular weight heparin in primary brain tumor patients. 2. To determine the incidence of deep venous thrombosis or pulmonary embolism in brain tumor patients who will be receiving Tinzaparin as primary prophylaxis. 3. To determine the overall survival of patients with malignant glioma who receive Tinzaparin. 4. To determine the bone density before and after prophylactic Tinzaparin.
Interventions
- DRUG Innohep
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-02 |
| Est. Completion | 2009-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00629447
The ClinicalTrials.gov registry entry for NCT00629447 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Innohep is the first listed.
NCT00629447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00629447 about?
NCT00629447 is a clinical study titled "Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients". To determine the safety of prophylaxis with Tinzaparin low molecular weight heparin in primary brain tumor patients. 2. To determine the incidence of deep venous thrombosis or pulmonary embolism in brain tumor patients who will be receiving Tinzaparin as primary prophylaxis. 3. To determine the over...
What is the current status of trial NCT00629447?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2004-02. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00629447?
The interventions under investigation include: Innohep (DRUG).
Who is sponsoring clinical trial NCT00629447?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.